Trial Profile
A phase IIa, randomized, placebo-controlled, double-blind, parallel study to investigate the efficacy of EG-Mirotin subcutaneously administered in multiple doses on diabetic macular edema in diabetic retinopathy patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2019
Price :
$35
*
At a glance
- Drugs EGT 022 (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Sponsors EyeGene
- 26 Jun 2019 Status changed from recruiting to discontinued.
- 31 Aug 2017 New trial record